Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Silibinin - Rottapharm Madaus

Next Previous
Drug Profile

Silibinin - Rottapharm Madaus

Alternative Names: Legalon; Legalon SIL; silybin - Rottapharm Madaus

Latest Information Update: 15 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rottapharm Madaus
  • Developer Rottapharm Madaus; University of Leipzig
  • Class Antidotes; Antihyperlipidaemics; Antivirals; Chromans; Dioxins; Hepatoprotectants
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity No

Highest Development Phases

  • Marketed Liver disorders; Poisoning
  • Discontinued Hepatitis C

Most Recent Events

  • 24 Oct 2018 Discontinued - Phase-II for Hepatitis C (Adjunctive treatment, Treatment-experienced) in Germany (IV)
  • 04 Mar 2015 Rottapharm Madaus withdraws the phase II/III HEPASIL trial prior to enrolment for Hepatitis C (treatment-naive) in Egypt (NCT01871662)
  • 19 Feb 2015 University of Leipzig completes a phase II trial in Hepatitis C (Adjunctive treatment, Treatment-experienced) in Germany (EudraCT2012-004442-15) before February 2015
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top